Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Plans Business Suspension Order for Novartis
The Ministry of Health, Labor and Welfare (MHLW) on February 3 notified Novartis Pharma of its plan to issue a business suspension order over the company’s flawed reporting of adverse drug reactions (ADRs). The Japan arm of Swiss pharma giant…
To read the full story
Related Article
- Novartis Slapped with 15 Day Biz Suspension over Flawed ADR Reporting
February 27, 2015
- Novartis Pharma Should Take Suspension Order Serious: Mr Tsuchiya of JSHP
February 5, 2015
- Novartis Confirms Additional Cases of Employee Involvement in IIT, but Denies Falsification or Manipulation of Data
December 18, 2014
REGULATORY
- Japan Pharma Investment Subgroup to Hold 1st Meeting September 18
September 14, 2026
- Japan Formally Joins Project Orbis for Cancer Drug Reviews
September 14, 2026
- MHLW Seeks 20.6 Billion Yen for MCM Stockpiles, Revenue Guarantees
September 14, 2026
- Japan Panel Backs Mandatory Medical Data Sharing by Major Hospitals
September 14, 2026
- Atopic Dermatitis Proactive Therapy to Be Exempt from OTC-Like Drug Charge
September 14, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…